SCNI
HEALTHCAREScinai Immunotherapeutics Ltd
Live · NASDAQ · May 9, Close
What's Moving SCNI Today?
No stock-specific AI insight has been generated for SCNI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.57
Fundamentals
Trading
SCNI News
17 articles- Scinai Immunotherapeutics Announces $2.61 Million Private Placement FinancingYahoo Finance·Apr 24, 2026
- Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 PrioritiesYahoo Finance·Apr 6, 2026
- Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm CollaborationYahoo Finance·Apr 1, 2026
- Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026Yahoo Finance·Mar 19, 2026
- Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid PriceYahoo Finance·Mar 16, 2026
- Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of ConceptYahoo Finance·Mar 2, 2026
- Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish PlatformYahoo Finance·Feb 25, 2026
- Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with RecipharmYahoo Finance·Feb 17, 2026
- Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthILYahoo Finance·Jan 7, 2026
- Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline AdvancesYahoo Finance·Dec 2, 2025
- Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO CapabilitiesYahoo Finance·Oct 6, 2025
- Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance SheetYahoo Finance·Sep 2, 2025
- Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TENYahoo Finance·Jul 29, 2025
- Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"Yahoo Finance·Jun 26, 2025
- Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025Yahoo Finance·Jun 12, 2025
- Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.Yahoo Finance·Jun 5, 2025
- Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash BurnYahoo Finance·May 30, 2025
All 17 articles loaded
Price Data
52-Week Range
$0.57
Fundamentals
Trading
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd is a cutting-edge biotechnology company specializing in the development of innovative immunotherapy solutions aimed at treating cancer and autoimmune disorders. Utilizing its proprietary immune modulation platform, Scinai is advancing a robust clinical pipeline that focuses on delivering transformative therapies to improve patient outcomes. With a highly experienced leadership team and a commitment to rigorous research, the company is well-positioned to capitalize on the growing demand for advanced immunotherapeutics in the global healthcare landscape. Strategic partnerships further enhance Scinai's potential for significant growth, establishing it as a key player in the biopharmaceutical sector.